那格列奈对照瑞格列奈治疗2型糖尿病疗效与安全性的Meta分析  

Meta-analysis on Efficacy and Safety for Control Study of Nateglinide and Repaglinide in Type 2 Diabetes Mellitus

作　　者：李义秀[1] 徐睿来[1] 章新晶[1] 梁佳[1] 谢珊珊[1] 

机构地区：[1]南昌大学第二附属医院药学部,南昌330006

出　　处：《中国医院用药评价与分析》2016年第1期48-53,共6页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：中国药学会"十二五科技支撑计划"课题(NO.2013BAI06B04Y023090)

摘　　要：目的:评价那格列奈对照瑞格列奈治疗2型糖尿病的疗效与安全性。方法:分别在Pubmed、Medline、Cochrane、CNKI、万方、维普等数据库中检索有关文献,并进行质量评估,对符合要求的26篇随机对照试验数据进行Meta分析。结果:经治疗后糖化血红蛋白、空腹血糖值均较治疗前显著降低,2组自身比较差异有统计学意义(P<0.05)。2组治疗前后下降差值组间比较:糖化血红蛋白[MD=0.17,95%CI=(-0.06,0.41),P=0.15]、餐后2 h血糖[MD=0.05,95%CI=(-0.36,0.46),P=0.80]差异均无统计学意义;空腹血糖下降差值比较差异有统计学意义,瑞格列奈组要优于那格列奈组[MD=0.41,95%CI=(0.08,0.74),P=0.01];不良反应发生率[OR=0.93,95%CI=(0.68,1.28),P=0.67]差异无统计学意义。结论:那格列奈治疗2型糖尿病疗效确切,安全性和耐受性良好。OBJECTIVE： To evaluate the efficacy and safety of control study on nateglinide and repaglinide in type 2diabetes mellitus. METHODS： the related literature from Pubmed,Medline,Cochrane,CNKI,Wanfang database and VIP database was retrieved,the quality of the selected literature was evaluated and Meta-analysis was conducted on the data of26 RCTs that accorded with requirements. RESULTS： After treatment,the Hb A1 c and the fasting blood glucose（ FBG） were significantly decreased compared with before treatment,the difference was statistically significant by self-comparison in two groups（ P 〈0. 05）. To compare the drop difference between two groups before and after treatment： the difference of Hb A1c[MD =0. 17,95%CI =（-0. 06,0. 41）,P =0. 15]and 2 hour postprandial blood glucose [MD =0. 05,95% CI =（-0. 36,0. 46）,P = 0. 80]had no statistical significance between 2 groups. There was statistical significance in the drop difference of FBG between 2 groups,and repaglinide group was better than nateglinide group [MD = 0. 41,95% CI =（ 0. 08,0. 74）,P =0. 01]; The incidence of ADR had no statistical significance [OR = 0. 93,95% CI =（ 0. 68,1. 28）,P = 0. 67].CONCLUSIONS： The curative effects of nateglinide is exact,safe and well tolerated.

关 键 词：那格列奈 瑞格列奈 2型糖尿病 META分析 

分 类 号：R977.15[医药卫生—药品]